Iovance Biotherapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Iovance Biotherapeutics reports increased Amtagvi revenue and ongoing clinical trials, alongside a net loss of $391.0 million for fiscal year 2025.
NASDAQ
Iovance Biotherapeutics reports its 2024 financial results, highlighting the commercial launch of Amtagvi and continued advancement of its TIL therapy pipeline.
NASDAQ
Iovance Biotherapeutics' 10-K filing highlights the FDA approval and commercial launch of Amtagvi, along with progress in its TIL therapy pipeline and manufacturing capabilities.